NCT00686595View on ClinicalTrials.gov

A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 1, 2007

Primary Completion Date

October 1, 2009

Study Completion Date

October 1, 2009

Conditions
Psoriasis
Interventions
BIOLOGICAL

Infliximab

Infliximab 5 mg/kg IV infusion.

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00686595 - A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133) | Biotech Hunter | Biotech Hunter